Lexeo Therapeutics to Participate in Leerink Global Healthcare Conference

The clinical-stage genetic medicine company will present at the upcoming industry event.

Mar. 3, 2026 at 7:31am

Got story updates? Submit your updates here. ›

Lexeo Therapeutics, a New York City-based clinical-stage genetic medicine company focused on developing treatments for cardiovascular diseases, announced that it will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 in Miami, Florida. The event will be webcast live on the company's website.

Why it matters

Lexeo's participation in the high-profile Leerink Global Healthcare Conference provides an opportunity for the company to showcase its pipeline of genetic medicine candidates targeting serious cardiovascular conditions with high unmet need, including Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy.

The details

The fireside chat will take place at 10:00 a.m. ET on March 10, 2026 during the Leerink Global Healthcare Conference in Miami, Florida. A live webcast of the event will be available on Lexeo's website under the News & Events tab in the Investors section, and a replay will also be posted on the site following the presentation.

  • The fireside chat will take place on Tuesday, March 10, 2026 at 10:00 a.m. ET.

The players

Lexeo Therapeutics

A New York City-based, clinical-stage genetic medicine company dedicated to developing treatments for cardiovascular diseases.

Got photos? Submit your photos here. ›

The takeaway

Lexeo's participation in the Leerink Global Healthcare Conference highlights the company's progress in advancing its pipeline of genetic medicine candidates targeting serious cardiovascular conditions, providing investors and the broader industry an opportunity to learn more about Lexeo's innovative approach to reshaping heart health.